Findings

What do systematic reviews say?

3 questions · 5 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Idraparinux vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

2 findings from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.71 [0.34, 1.47]
1 study · 2904 participants
Very low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [0.35, 3.56]
1 study · 270 participants
Low

Low molecular weight heparin and idraparinux vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

2 findings from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 3.76 [0.5, 28.19]
1 study · 659 participants
Very low